Pembrolizumab, as a PD-1 inhibitor, blocks the interaction between PD-1 and its ligand PD-L1, restoring T-cell function and enhancing the immune system’s ability to recognize and eliminate cancer cells (Gu et al., 2024). Here, CD274 is linked to cancer.